|
2
|
41
|
1l3yA |
Integrin egf-like module 3 from the beta-2 subunit |
|
6
|
53
|
1egfA |
Solution structure of murine epidermal growth factor determined by nmr spectroscopy and refined by energy minimization with restraints |
|
3
|
46
|
1f7eA |
The first egf-like domain from human blood coagulation fvii, nmr, 20 structures |
|
28
|
85
|
1couA |
Anticoagulant protein from the nematode ancylostoma caninum |
|
3
|
40
|
1fsbA |
Structure of the egf domain of p-selectin, nmr, 19 structures |
|
4
|
46
|
1ff7A |
The first egf-like domain from human blood coagulation fvii (fucosylated at ser-60), nmr, 20 structures |
|
12
|
53
|
1apqA |
Structure of the egf-like module of human c1r, nmr, 19 structures |
|
2
|
49
|
1gk5A |
Solution structure the megf/tgfalpha44-50 chimeric growth factor |
|
1
|
53
|
1ephA |
Three-dimensional nuclear magnetic resonance structures of mouse epidermal growth factor in acidic and physiological ph solutions |
|
6
|
56
|
1ccvA |
Nmr solution structure of apis mellifera chymotrypsin inhibitor (amci). |
|
4
|
42
|
1ccfA |
How an epidermal growth factor (egf)-like domain binds calcium-high resolution nmr structure of the calcium form of the nh2-terminal egf-like domain in coagulation factor x |
|
1
|
53
|
1epjA |
Three-dimensional nuclear magnetic resonance structures of mouse epidermal growth factor in acidic and physiological ph solutions |
|
2
|
45
|
1a3pA |
Role of the 6-20 disulfide bridge in the structure and activity of epidermal growth factor, nmr, 20 structures |
|
6
|
41
|
1bf9A |
N-terminal egf-like domain from human factor vii, nmr, 23 structures |
|
7
|
67
|
1hrfA |
Solution structure of the epidermal growth factor-like domain of heregulin-alpha, a ligand for p180erb4 |
|
4
|
42
|
1apoA |
Three-dimensional structure of the apo form of the n-terminal egf-like module of blood coagulation factor x as determined by nmr spectroscopy and simulated folding |
|
4
|
62
|
1atdA |
High-resolution structure of ascaris trypsin inhibitor in solution: direct evidence for a ph induced conformational transition in the reactive site |
|
3
|
83
|
1dqbA |
Nmr structure of thrombomodulin egf(4-5) |
|
4
|
46
|
1k36A |
Nmr structure of human epiregulin |
|
3
|
82
|
1hz8A |
Solution structure and backbone dynamics of a concatemer of egf-homology modules of the human low density lipoprotein receptor |
|
0
|
40
|
1adxA |
Fifth egf-like domain of thrombomodulin (tmegf5), nmr, 14 structures |
|
6
|
80
|
1hj7A |
Nmr study of a pair of ldl receptor ca2+ binding epidermal growth factor-like domains, 20 structures |
|
12
|
63
|
1haeA |
Heregulin-alpha epidermal growth factor-like domain, nmr, 20 structures |
|
5
|
96
|
1cejA |
Solution structure of an egf module pair from the plasmodium falciparum merozoite surface protein 1 |
|
7
|
60
|
1hx2A |
Solution structure of bsti, a trypsin inhibitor from bombina bombina. |
|
2
|
62
|
1ateA |
High-resolution structure of ascaris trypsin inhibitor in solution: direct evidence for a ph induced conformational transition in the reactive site |
|
6
|
50
|
1ioxA |
Nmr structure of human betacellulin-2 |
|
6
|
82
|
1emoA |
Nmr study of a pair of fibrillin ca2+ binding epidermal growth factor-like domains, 22 structures |
|
8
|
52
|
3u7uG |
Crystal structure of extracellular region of human epidermal growth factor receptor 4 in complex with neuregulin-1 beta |
|
12
|
56
|
3sw2A |
X-ray crystal structure of human fxa in complex with 6-chloro-n-((3s)-2-oxo-1-(2-oxo-2-((5s)-8-oxo-5,6-dihydro-1h-1,5-methanopyrido[1,2-a][1,5]diazocin-3(2h,4h,8h)-yl)ethyl)piperidin-3-yl)naphthalene-2-sulfonamide |
|
12
|
55
|
5l2yL |
Factor viia in complex with the inhibitor 1-[(2r,15r)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,20-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl] cyclobutane-1-carboxylic acid |
|
195
|
551
|
5kirA |
The structure of vioxx bound to human cox-2 |
|
13
|
58
|
5l2zL |
Factor viia in complex with the inhibitor 1-[(2r,15r)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-7-yl]cyclohexane-1-carboxylic acid |
|
13
|
56
|
5l30L |
Factor viia in complex with the inhibitor (2r,15r)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(1h-tetrazol-5-yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione |
|
5
|
40
|
5kn5C |
Tgfalpha/epiregulin complex with neutralizing antibody ly3016859 |
|
200
|
552
|
5jw1A |
Crystal structure of celecoxib bound to s121p murine cox-2 mutant |
|
195
|
551
|
5jvyA |
Crystal structure of s121p murine cox-2 mutant |
|
10
|
51
|
5k0hB |
Human factor xa in complex with synthetic inhibitor benzylsulfonyl-dser(benzyl)-gly-4-amidinobenzylamide |
|
200
|
552
|
5jvzA |
Crystal structure of flurbiprofen bound to s121p murine cox-2 mutant |
|
8
|
51
|
5jbcE |
Crystal structure of factor ixa variant v16i k98t y177t i213v in complex with ppack |
|
11
|
51
|
5jb9E |
Crystal structure of factor ixa k98t variant in complex with ppack |
|
10
|
51
|
5jb8E |
Crystal structure of factor ixa variant k98t in complex with egr-chloromethylketone |
|
11
|
51
|
5jbbE |
Crystal structure of factor ixa variant v16i k98t y177t i213v in complex with egr-chloromethylketone |
|
192
|
551
|
5ikqA |
The structure of meclofenamic acid bound to human cyclooxygenase-2 |
|
200
|
551
|
5ikvA |
The structure of flufenamic acid bound to human cyclooxygenase-2 |
|
203
|
551
|
5iktA |
The structure of tolfenamic acid bound to human cyclooxygenase-2 |
|
174
|
552
|
6coxA |
Cyclooxygenase-2 (prostaglandin synthase-2) complexed with a selective inhibitor, sc-558 in i222 space group |
|
51
|
278
|
5cknA |
The cub1-egf-cub2 domains of rat mbl-associated serine protease-2 (masp-2) bound to ca2+ |
|
54
|
278
|
5cisA |
The cub1-egf-cub2 domains of rat mbl-associated serine protease-2 (masp-2) bound to ca2+ |
|
12
|
52
|
4zhaB |
Factor xa complex with gtc000102 |
